talapro-2 study of talazoparib/enzalutamide in prostate cancer: stephen freedland and neeraj agarwal
Published 7 months ago • 324 plays • Length 18:58Download video MP4
Download video MP3
Similar videos
-
14:30
mcrpc care: reducing progression risk by combining enzalutamide and talazoparib
-
0:52
talapro-2 study design for 1l in mcrpc patients - now fda approved | #oncology #cancer #2023
-
1:44
talapro-2: exposure-safety of talazoparib enzalutamide in mcrpc
-
0:39
talapro-2: rpfs and os of talazoparib and enzalutamide in mcrpc
-
1:30:47
allycon 2020: advances in precision treatment and therapies for colorectal cancer
-
5:23
stories of advanced prostate cancer remissions | ask a prostate cancer expert, mark scholz, md
-
3:03
apa itu imunoterapi? - dr. shum weng yoon - mahkota medical centre
-
1:02
dr. agarwal on the safety profile of enzalutamide/talazoparib in mcrpc
-
1:37
dr. agarwal on the talapro-2 trial in mcrpc
-
1:56
talapro-2: exposure efficacy of talazoparib and enzalutamide in mcrpc
-
1:38
novel combination therapy regimen shows promising results for prostate cancer
-
5:52
talapro-1: phase ii study of talazoparib in patients with dna damage repair alterations and mcrpc
-
1:50
dr. agarwal on pfs2 data from the titan trial in mcspc
-
1:16
potential new treatment for advanced prostate cancer
-
2:12
dr. neeraj agarwal on prostvac and other immunotherapies in prostate cancer
-
1:12
dr. agarwal on second-line therapy selection in metastatic rcc
-
0:56
dr. trabulsi defines locally advanced prostate cancer
-
1:09
considerations for apalutamide versus enzalutamide in prostate cancer treatment
-
0:57
dr. agarwal on the tolerability of apalutamide in mcspc
-
6:54
talapro-2: toxicities and treatment duration
-
1:19
talapro-2: exploratory analyses of hrr gene subgroups in mcrpc
-
24:19
demystifying clinical trials in prostate cancer